Login to Your Account

Chi-Med's savolitinib hits phase II endpoints in Met-driven PRCC

By Shannon Ellis
Staff Writer

Tuesday, February 21, 2017

SHANGHAI – Hutchison China Meditech Ltd. (Chi-Med) and its partner, Astrazeneca plc, of London, shared phase II safety and efficacy data for savolitinib in patients with PRCC, a fatal form of kidney cancer.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription